Next Article in Journal
Autologous Transplantation for Older Adults with AML
Next Article in Special Issue
Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase
Previous Article in Journal
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
Previous Article in Special Issue
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Cancers 2018, 10(9), 337; https://doi.org/10.3390/cancers10090337

Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer

1
Indian Institute of Science Education and Research, Pune 411008, India
2
Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI 54911, USA
*
Author to whom correspondence should be addressed.
Received: 25 July 2018 / Revised: 13 September 2018 / Accepted: 17 September 2018 / Published: 18 September 2018
(This article belongs to the Special Issue The Tumor Microenvironment of High Grade Serous Ovarian Cancer)
  |  
PDF [1078 KB, uploaded 18 September 2018]
  |  

Abstract

Aerobic glycolysis is an important metabolic adaptation of cancer cells. There is growing evidence that oxidative phosphorylation is also an active metabolic pathway in many tumors, including in high grade serous ovarian cancer. Metastasized ovarian tumors use fatty acids for their energy needs. There is also evidence of ovarian cancer stem cells privileging oxidative phosphorylation (OXPHOS) for their metabolic needs. Metformin and thiazolidinediones such as rosiglitazone restrict tumor growth by inhibiting specific steps in the mitochondrial electron transport chain. These observations suggest that strategies to interfere with oxidative phosphorylation should be considered for the treatment of ovarian tumors. Here, we review the literature that supports this hypothesis and describe potential agents and critical control points in the oxidative phosphorylation pathway that can be targeted using small molecule agents. In this review, we also discuss potential barriers that can reduce the efficacy of the inhibitors of oxidative phosphorylation. View Full-Text
Keywords: high grade serous ovarian cancer; metabolism; mitochondria; oxidative phosphorylation; oxidative stress; biguanides; atovaquone; plumbagin; thiazolidinediones; ubiquinone; Nrf-2 high grade serous ovarian cancer; metabolism; mitochondria; oxidative phosphorylation; oxidative stress; biguanides; atovaquone; plumbagin; thiazolidinediones; ubiquinone; Nrf-2
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Nayak, A.P.; Kapur, A.; Barroilhet, L.; Patankar, M.S. Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer. Cancers 2018, 10, 337.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top